Recently At InnoSer
OUR INNOVATIVE METHODS
Combining In-Vivo And In-Vitro
By our state-of-the-art methods from organoids to genetically engineered mice, we provide reliability and transferability in your results.
Low success rates of drugs that are able to go from bench to the clinic continue to disappoint not only researchers and pharmaceutical companies but also patients and their families. The resulting expenses affect the costs of all drugs that reach the market.
This calls for more stringent criteria at the preclinical phase, ensuring only the drugs that are effective and safe for humans continue to the clinical phases. InnoSer excels in combining in vitro and in vivo disease modelling to offer the most reliable screening platforms.
By developing in-vitro technologies and knowledge that offer higher predictive capacity, we support the transition to a world that relies less on animal testing.
GET IN TOUCH WITH US
Tell Us About Your Work
We always keep close contact with our customers to identify and understand their needs better. All our services can be customized for your project requirements.
OUR CLIENTS ABOUT US
Academic And Commercial Expertise
“We have worked with InnoSer in several projects and what truly distinguished them was flexibility, keeping tight time lines and a deep scientific knowledge in GEMM generation. The latter was proven in a large project with several leading Dutch universities called project IMPAct, which was successfully finalized in November 2014.”
Prof. Dr. Marten Smidt, Swammerdam Institute of Life Sciences, University of Amsterdam
“Since two years I am working with InnoSer and my research group is extremely happy with their service levels, GEMM support and pro-active communication. By working with InnoSer we were able to reduce cost by highly efficient colony management and making use of their cryopreservation program.”
Prof. Dr. Leon de Windt, Maastricht University